Search

Displaying results 7051 - 7060 of 7452 in total
  1. Drug

    Totrombopag

    go.drugbank.com/drugs/DB05930
    Investigational

    SB-559448 is a small-molecule drug that mimics the activity of thrombopoietin (TPO), a protein factor that promotes growth and production of blood platelets. This drug is developed by GlaxoSmithKline and used to treat Thrombocytopenia.Th...

  2. Drug

    DA-697b

    go.drugbank.com/drugs/DB06001
    Experimental

    DA-967b is an investigational antiplatelet agent that inhibits collagen and ristocetin-mediated platelet activation.

  3. Drug

    Fradafiban

    go.drugbank.com/drugs/DB06472
    Experimental

  4. Drug

    Taranabant

    go.drugbank.com/drugs/DB06624
    Investigational

  5. Drug

    Anacetrapib

    go.drugbank.com/drugs/DB06630
    Investigational

  6. Drug

    Valrocemide

    go.drugbank.com/drugs/DB06657
    Experimental

  7. Drug

    Omapatrilat

    go.drugbank.com/drugs/DB00886
    Experimental

    Omapatrilat is an investigational drug that inhibits both neutral endopeptidase (NEP) and angiotensin converting enzyme (ACE). The inhibition of NEP elevates natriuretic peptide levels, increasing excretion of sodium in urine, dilating b...

  8. Drug

    ND1251

    go.drugbank.com/drugs/DB05132
    Experimental

    ND1251 is an orally active phosphodiesterase-4 (PDE4) inhibitor, a mechanism clinically proven to play a role in alleviating symptoms of depression. ND1251 is a very potent compound with a large safety margin. ND1251 may also have applic...

  9. Drug

    CR002

    go.drugbank.com/drugs/DB05139
    Investigational

    CR002 is a novel investigational fully human monoclonal antibody that blocks the activity of excess platelet-derived growth factor-D (PDGF-D), a target shown to play a role in kidney inflammation. This is a novel therapeutic approach to ...

  10. Drug

    TAK-475

    go.drugbank.com/drugs/DB05317
    Investigational

    TAK-475 is a "squalene synthase inhibitor", a type of cholesterol-lowering drug that has not yet been brought to market.